Berlin, Germany, and Research Triangle Park, N.C., USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaRegenerative Medicine ...
Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...
There are many good men but that’s not the point. All it takes is one bad one, one look to make your insides drop ...
Parkinson's Disease Treatment Market Aging Populations and Advancements in Deep Brain Stimulation, Gene Therapy, and Medications Fuel Marke ...
GOTHENBURG, SE / ACCESS Newswire / February 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 12, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company d ...
A County Durham resident has become one of the first patients in England to benefit from a groundbreaking new treatment for ...
The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...
According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...
GOTHENBURG, SE / ACCESS Newswire / February 7, 2025 /IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback